Precision Biosensor

Precision Biosensor OCF Margin

The Operating Cash Flow Margin of Precision Biosensor (335810.KQ) as of Oct 28, 2026 is -7.59 %. In the previous year, Operating Cash Flow Margin was -7.55 % — a change of 0.60% (lower).

OCF Margin

-7.59 %

YoY

0.60%

Last updated:

Operating Cash Flow Margin of Precision Biosensor is 2025 -7.59 % . Operating Cash Flow Margin of Precision Biosensor was 2024 -7.55 % . It decreases by 0.60% lower compared to the previous year.

The Precision Biosensor OCF Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

OCF Margin
Date
OCF Margin
Jan 1, 2018
-62.21 KRW
Jan 1, 2019
-33.47 KRW
Jan 1, 2020
-55.73 KRW
Jan 1, 2021
-28.79 KRW
Jan 1, 2022
-12.59 KRW
Jan 1, 2023
-9.58 KRW
Jan 1, 2024
-7.55 KRW
Jan 1, 2025
-7.59 KRW
The Precision Biosensor OCF Margin history
YEAROCF MarginYoY
-7.59 %+0.60%
-7.55 %-21.21%
-9.58 %-23.93%
-12.59 %-56.27%
-28.79 %-48.33%
-55.73 %+66.52%
-33.47 %-46.20%
-62.21 %-2.39%
-63.73 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Precision Biosensor Stock analysis

What does Precision Biosensor do? Precision Biosensor Inc. generates revenue through the sale of portable immunoassay diagnostic devices and cartridges. The testers, which are portable devices using colorimetric and time-resolved fluorescence, are sold for on-site diagnosis of acute heart disease, metabolism, and inflammatory diseases. The cartridges, designed for gold absorption and time-resolved fluorescence analysis, are used in diagnostic equipment to check the same conditions. The company targets domestic and overseas markets including Europe, China, the Middle East, and Southeast Asia for its products. The firm's primary customers are healthcare providers and diagnostic laboratories seeking rapid, on-site testing solutions. These segments value the portability and speed of the testers, which enable immediate diagnosis without laboratory processing. The cartridges complement the testers by providing consumable components for consistent diagnostic accuracy across various medical conditions. Precision Biosensor Inc. focuses on markets where demand for point-of-care diagnostics is growing, particularly in regions with expanding healthcare infrastructure. The company's product line addresses acute heart disease, metabolism, and inflammatory diseases, aligning with global health priorities. Sales in Europe, China, the Middle East, and Southeast Asia reflect the company's strategy to serve both developed and emerging healthcare systems. Precision Biosensor is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Precision Biosensor stock

Operating Cash Flow Margin of Precision Biosensor is -7.59 % in 2025.

Operating Cash Flow Margin of Precision Biosensor changed from -7.55 % to -7.59 %, representing a 0.60% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Operating Cash Flow Margin Precision Biosensor since 2006 – with annual values, charts, and detailed analysis.

OCF margin measures the percentage of revenue converted into operating cash flow. It indicates cash generation efficiency from core business operations.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Operating Cash Flow Margin's Precision Biosensor with sector peers and the industry average to assess whether it is attractive.

To evaluate Operating Cash Flow Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Operating Cash Flow Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Margins — Precision Biosensor

Gross MarginEBIT MarginEBITDA MarginNet MarginFCF MarginR&D / RevenueTax RatePayout RatioPre-Tax MarginOCF MarginSGA/RevenueOpEx/RevenueReinvestment Rate

All Key Metrics — Precision Biosensor